Pharmacological and Biochemical Evaluation of Metformin, Glimepiride, and Voglibose in the Management of Type 2 Diabetes Mellitus.

Abstract

Introduction: Poor glycemic control was seen in most of the patients suffering from type 2 diabetes mellitus. Fixed dose combination of Metformin, Glimepiride, and Voglibose prescribed in patients with HbA1c more than 9.0% diabetic patients. The main is to study the effect of triple drug combination therapy in treating type 2 diabetes mellitus patients.

Aim: To study the effect of metformin + glimepiride + voglibose in the treatment of type 2 diabetes mellitus patients. 

Material and methods: the present study was carried out on 200 type 2 diabetes mellitus. Patients under inclusion criteria and ready to give informed consent forms were included in the study and treated with the combination of metformin + glimepiride voglibose. All the patients’ blood glucose levels and lipid profiles were estimated before taking drugs (baseline) and after 6 months of treatment, all the investigations were done again (after 6 months).

Results: The total number of patients included in the study was 200, among them; the majority was male with the age group of 51 – 60 years. All the patients HbA1c, FBS, PPBS, total cholesterol, triglycerides, HDL, LDL & VLDL. A higher Significant mean reduction was observed in HbA1c, FBS & PPBS (p<0.005). on lipid profile significant mean reduction was observed in TC (p 0.042), Triglycerides (p 0.034), LDL (p 0.045) & VLDL (p 0.050) and increased mean was observed in HDL (p0.050) after treatment with a triple-drug combination of metformin, glimepiride, and voglibose respectively.

Conclusion: Triple drug combination of metformin, glimepiride, and voglibose shows significant improvement in blood glucose and lipid levels in type 2 diabetes mellitus patients.